Serge Langford

Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials.

PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada.

DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada.

LQT Therapeutics, Inc. engages in the development of therapies for the treatment of all forms of Long QT Syndrome. The company was founded by Anthony Rosenzweig, Saumya Das and David Milan and is headquartered in Laval, Canada.

Founded in 2005, formerly Société Innovatech du Grand Montréal, Multiple Capital is a Montréal-based venture capital subsidiary of Collier Capital Ltd.

Topigen Pharmaceuticals, Inc. develops drugs for respiratory diseases. The firm focuses on discovery and development of multiple pathway therapies for respiratory diseases with primary emphasis on asthma, chronic obstructive pulmonary disease, and allergic rhinitis. The company was founded by Paolo Renzi in 2000 and is headquartered in Montréal, Canada.

Aurelium BioPharma Inc., develops therapeutics and diagnostics for the treatment of drug-resistant cancers. The company has developed several diagnostic tests for the detection of breast, ovarian as well as drug-resistant cancers. The firm has a strong drugable pipeline of novel targets and complimentary diagnostic products that are utilized in its strategic collaborations and out-licensing efforts. The company was founded in May 1998 and is headquartered in Laval, Canada.